Evidence map›Paper›PMID 30955140›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2019

Efficacy and Safety of Basal Analog Regimens in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Ting Hong, Jing Lu, Pengzi Zhang, Zhou Zhang, Qianyue Xu, Yunguang Li, Nan Cui, Ambar Grijalva, Erin M Murray, Michael A Del Aguila and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ting HongDepartment of Endocrinology, Drum Tower Hospital Affiliated with Nanjing University Medical School, Nanjing, China.
Jing LuDepartment of Endocrinology, Drum Tower Hospital Affiliated with Nanjing University Medical School, Nanjing, China.
Pengzi ZhangDepartment of Endocrinology, Drum Tower Hospital Affiliated with Nanjing University Medical School, Nanjing, China.
Zhou ZhangDepartment of Endocrinology, Drum Tower Hospital Affiliated with Nanjing University Medical School, Nanjing, China.
Qianyue XuDepartment of Endocrinology, Drum Tower Hospital Affiliated with Nanjing University Medical School, Nanjing, China.
Yunguang LiSanofi (China) Investment Co., Ltd., Shanghai Branch, China Medical Affairs, Shanghai, China.
Nan CuiSanofi (China) Investment Co., Ltd., Shanghai Branch, China Medical Affairs, Shanghai, China.
Ambar GrijalvaDoctor Evidence, Santa Monica, CA, USA.
Erin M MurrayDoctor Evidence, Santa Monica, CA, USA.
Michael A Del AguilaDoctor Evidence, Santa Monica, CA, USA.
Yan BiDepartment of Endocrinology, Drum Tower Hospital Affiliated with Nanjing University Medical School, Nanjing, China. biyan@nju.edu.cn.
Nanjing Drum Tower Hospital · CNSanofi (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study compared basal analog (BA: glargine U100/mL and detemir) and premix (PM: human, lispro and aspart biphasic) insulin regimens in terms of their efficacy and safety in type 2 diabetes mellitus patients.

methodsSearches of MEDLINE, Embase, and CENTRAL identified primary randomized controlled trials (RCTs) ≥ 12 weeks in duration that compared BA or PM insulin regimens in adults with T2DM, with ≥ 30 patients per arm. A systematic literature review and a pairwise meta-analysis were performed using a random effects model adjusted for between-study variability. Analyses were conducted based on frequency of bolus insulin and PM injections, PM ratio and type, BA type, race, follow-up period, and baseline glycosylated hemoglobin (HbA1c).

resultsTwenty-two primary RCTs with 9691 patients were included. The BA and PM regimens yielded similar changes in HbA1c and postprandial glucose levels, with a statistically significant reduction in fasting glucose [mean difference (MD) - 0.61 mmol/L (95% confidence interval (CI) - 0.90, - 0.32), I

conclusionWhen compared to PM regimens, BA regimens yielded similar efficacies and better safety profiles in patients with type 2 diabetes mellitus.

fundingSanofi (Shanghai, China).

Indexed as

Basal-bolus insulin therapyBasal insulin analoguesMeta-analysisPremix insulin therapySystematic reviewType 2 diabetes mellitus

Identifiers

PMID30955140
PMCPMC6531585
OpenAlexW2928197747

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.